Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Valent

Showing results (111-120 of 662) with videos related to

Pageof 67
Sort By:
International Journal of Molecular Sciences|December 15, 2018
Therapeutic Vulnerabilities in <i>FLT3</i>-Mutant AML Unmasked by PalbociclibIris Z Uras, Barbara Maurer, Sofie Nebenfuehr, et al.
International Journal of Molecular Sciences|April 3, 2021
Mediator-Related Symptoms and Anaphylaxis in Children with MastocytosisKnut Brockow, Katarzyna Plata-Nazar, Magdalena Lange, et al.
European Journal of Haematology|May 12, 2010
Refinements in response criteria in systemic mastocytosis: reply to a proposalPeter Valent, Cem Akin, Wolfgang R Sperr, et al.
Leukemia & Lymphoma|October 30, 2004
Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816VFrank Noack, Karl Sotlar, Martin Notter, et al.
Biological Chemistry|July 17, 2008
A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6Birgit Linhart, Nadine Mothes-Luksch, Susanne Vrtala, et al.
The Journal of Molecular Diagnostics : JMD|January 1, 2008
Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617FKarl Sotlar, Anja Bache, Florian Stellmacher, et al.
Hematology/Oncology Clinics of North America|October 17, 2003
Mast cell proliferative disorders: current view on variants recognized by the World Health OrganizationPeter Valent, Cem Akin, Wolfgang R Sperr, et al.
Wiener Klinische Wochenschrift|September 19, 2003
Treatment concepts for elderly patients with acute myeloid leukemiaWolfgang R Sperr, Alexander W Hauswirth, Friedrich Wimazal, et al.
The Journal of Allergy and Clinical Immunology|April 17, 2021
Metabolome and lipidome derangements during a severe mast cell activation event in a patient with indolent systemic mastocytosisThomas Boehm, Robin Ristl, Saijo Joseph, et al.
American Journal of Clinical Pathology|September 9, 2005
Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasiaManuela Krokowski, Karl Sotlar, Maria-Theresa Krauth, et al.
Pageof 67

Showing results (111-120 of 662) with videos related to

Sort By:
Pageof 67
International Journal of Molecular Sciences|December 15, 2018
Therapeutic Vulnerabilities in <i>FLT3</i>-Mutant AML Unmasked by PalbociclibIris Z Uras, Barbara Maurer, Sofie Nebenfuehr, et al.
International Journal of Molecular Sciences|April 3, 2021
Mediator-Related Symptoms and Anaphylaxis in Children with MastocytosisKnut Brockow, Katarzyna Plata-Nazar, Magdalena Lange, et al.
European Journal of Haematology|May 12, 2010
Refinements in response criteria in systemic mastocytosis: reply to a proposalPeter Valent, Cem Akin, Wolfgang R Sperr, et al.
Leukemia & Lymphoma|October 30, 2004
Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816VFrank Noack, Karl Sotlar, Martin Notter, et al.
Biological Chemistry|July 17, 2008
A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6Birgit Linhart, Nadine Mothes-Luksch, Susanne Vrtala, et al.
The Journal of Molecular Diagnostics : JMD|January 1, 2008
Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617FKarl Sotlar, Anja Bache, Florian Stellmacher, et al.
Hematology/Oncology Clinics of North America|October 17, 2003
Mast cell proliferative disorders: current view on variants recognized by the World Health OrganizationPeter Valent, Cem Akin, Wolfgang R Sperr, et al.
Wiener Klinische Wochenschrift|September 19, 2003
Treatment concepts for elderly patients with acute myeloid leukemiaWolfgang R Sperr, Alexander W Hauswirth, Friedrich Wimazal, et al.
The Journal of Allergy and Clinical Immunology|April 17, 2021
Metabolome and lipidome derangements during a severe mast cell activation event in a patient with indolent systemic mastocytosisThomas Boehm, Robin Ristl, Saijo Joseph, et al.
American Journal of Clinical Pathology|September 9, 2005
Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasiaManuela Krokowski, Karl Sotlar, Maria-Theresa Krauth, et al.
Pageof 67